Introduction: Coronavirus disease 2019 (COVID-19) can present with acute kidney injury (AKI). Although the rate of AKI among these patients is not high, their outcome could be much worse than the other patients. Serum creatinine rise along with other laboratory findings may help as a clinical predictor of COVID-19 disease prognosis. Objectives: We aimed to evaluate the incidence and possible predictors of AKI occurrence and its outcome during the COVID-19 pandemic. Patients and Methods: In a retrospective observational study of 946 hospital-admitted patients with confirmed COVID-19 between March 20, 2020 and May 9, 2020, we described AKI incidence and its stages along with their association with demographic data, comorbidities, habitual and past-medical history, and laboratory findings using STATA version 14. Results: The mean age of participants was 55.6 (±18.7) years of which 60.4% were male. The most and least frequent underlying diseases were hypertension and chronic liver disease, 20.1% and 1.5%, respectively. Among patients with AKI, 45.9% had a higher age mean and female sex was more prevalent. In addition, hypertension, ischemic heart disease, diabetes, and chronic renal disease were more common in patients with AKI compared to patients without AKI. Moreover, AKI patients had lower oxygen saturation and mean levels of lymphocytes and higher mean levels of LDH and CKMB in comparison with no AKI group on admission. Overall, 80% of the patients were discharged (i.e. alive), of which 63.7% were non-severe patients and 19.4% of the patients expired during hospitalization. Conclusion: Comorbidities were more prevalent among AKI groups. Female and older patients were more prone to AKI during COVID-19 progression. The level of CK-MB was also higher in AKI group, suggesting probable cardiac injury. Lymphopenia and leukocytosis may be poor-prognostic factors for both AKI and COVID-19.
Objectives: The present study seeks to provide insight into managing patients with chronic kidney disease (CKD) infected with COVID-19.Methods: Patients with COVID-19 with CKD were included in the study. The eligible patients were divided into four groups: 1) patients who were not on dialysis, 2) patients on maintenance dialysis, 3) patients who underwent dialysis following COVID-19, 4) patients with a history of a kidney transplant. After reviewing clinical charts, nursing records, laboratory findings, radiological reports, and other medical records of CKD patients with COVID-19 confirmed infection, clinical presentation, laboratory data, radiology findings, and results were extracted from documented medical records. The epidemiological, clinical, laboratory and outcome characteristics of the subgroups were evaluated and compared.Results: Seventy-eight patients were included into the study. Hypertension (50 cases, 72.5%), diabetes (44 cases, 63.8%), and Cardiovascular disease (26 cases, 38.2%) were the most common risk factors in the studied patients. Among all participants, 40 (52.6%) patients died. The most common symptom was dyspnea (56.6%), followed by dry cough (38.7%). Comparison of blood, inflammatory, biochemical, and clinical indices among the patients' groups show that LDH (P=0.022), AST (P=0.038), and ALT (P= 0.004) indices were significantly different between groups of patients. According to the results in Table 3, Unilateral ground-glass opacity (GGO) in the radiological findings of the Nondialysis CKD group was significantly (P=0.50) higher than the other groups. Conclusion:It can be concluded that CKD is one of the critical factors that can cause poor prognosis in COVID-19 patients.
Background: Chronic kidney disease (CKD) patients are a large population and of significant importance. Except for having an underlying disease, they have some other risk factors, for example, old age, impaired immune function, and other comorbidities that make them more susceptible to the new SARS-COV2 infection.Methods: As data on CKD patients with SARS-CoV-2 Infection is limited, we decided to carry out a cross-sectional study at Labbafinezhad Hospital on 78 CKD patients with approved COVID-19 infection either on dialysis or not. We have also incorporated CKD patients with kidney transplant history. Results: The mean age of the patients was 64.04 years, including 53 women and 25 men. Among all symptoms, dyspnea (19.2%) was the most prevalent one. Laboratory data analysis shows an increase in LDH, Creatinine, and ESR and CRP levels. The most common finding on chest CT-Scan was bilateral ground-glass opacity detected in 31 (86.1%) patients, followed by pleural effusion (12.8%) and atelectasis (19%). Among included patients, 53 (74.6%) had hypoxia (o2 saturation 94% and lower), 47 (81%) had tachypnea (respiratory rate over 16) and 9 (23.1%) had some reduction in the level of consciousness (GCS lower than 15). Conclusion: Due to the important effect of underlying medical conditions on the outcome of COVID-19 patients, evaluation of clinical manifestations, radiologic findings, laboratory data, and outcome of COVID-19 patients with chronic kidney disease is important to establish a perspective for physicians to manage CKD patients.
Aim: The present study seeks to provide insight into the management of patients with chronic kidney disease (CKD) infected with COVID-19.Material and methods: Patients with COVID-19 were included in the study if they met the inclusion criteria. 78 eligible patients were divided into four groups. After reviewing clinical charts, nursing records, laboratory findings, radiological reports and other medical records of CKD patients with COVID-19 confirmed infection, clinical presentation, laboratory data, radiology findings, and results were extracted from documented medical records using data collection forms. laboratory tests were performed again before discharge. Independent t-test, paired t-test, and chi-square were used to compare the clinical features of patients with COVID-19. A P< 0.05 was considered to indicate statistical significance. All the statistical analyses were performed by the SPSS. v 26.0.Results: Hypertension (72.5%), diabetes (63.8%), and Cardiovascular disease (38.2%) were the most common among patients, respectively. Among all participants, 40 (52.6%) patients died. The most common symptom was dyspnea (56.6%), followed by dry cough (38.7%). Comparison of blood, inflammatory, biochemical, and clinical indices between the four groups in patients show that LDH (P=0.022), AST (P=0.038), and ALT (P= 0.004) indices were significantly different between groups of patients. According to the results in Table 3, Unilateral ground-glass opacity (GGO) in the radiological findings of the Non-dialysis CKD group was significantly (P=0.50) higher than the other groups.Conclusion: It can be concluded that CKD is an important factor that can cause poor prognosis in COVID-19 patients.
Background: Chronic kidney disease (CKD) patients are a large population and of significant importance. Except for having an underlying disease, they have some other risk factors, for example, old age, impaired immune function, and other comorbidities that make them more susceptible to the new SARS-COV2 infection.Methods: As data on CKD patients with SARS-CoV-2 Infection is limited, we decided to carry out a cross-sectional study at Labbafinezhad Hospital on 78 CKD patients with approved COVID-19 infection either on dialysis or not. We have also incorporated CKD patients with kidney transplant history. Results: The mean age of the patients was 64.04 years, including 53 women and 25 men. Among all symptoms, dyspnea (19.2%) was the most prevalent one. Laboratory data analysis shows an increase in LDH, Creatinine, and ESR and CRP levels. The most common finding on chest CT-Scan was bilateral ground-glass opacity detected in 31 (86.1%) patients, followed by pleural effusion (12.8%) and atelectasis (19%). Among included patients, 53 (74.6%) had hypoxia (o2 saturation 94% and lower), 47 (81%) had tachypnea (respiratory rate over 16) and 9 (23.1%) had some reduction in the level of consciousness (GCS lower than 15). Conclusion: Due to the important effect of underlying medical conditions on the outcome of COVID-19 patients, evaluation of clinical manifestations, radiologic findings, laboratory data, and outcome of COVID-19 patients with chronic kidney disease is important to establish a perspective for physicians to manage CKD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.